|
市場調查報告書
分子診斷的未來：革新的技術促進了個別化醫療的市場機會
The Future of Molecular Diagnostics: Innovative technologies driving market opportunities in personalized medicine
|
分子診斷的未來：革新的技術促進了個別化醫療的市場機會 是由出版商Business Insights在2010年06月所出版的。
這份英文市場調查報告書包含Pages: 191 價格從美金3835起跳。
分子診斷可以早期觀測傳染病與早期癌症，對體外診斷製造商而言看來今後會提供越來越重要的商業機會
本報告書為現在以及將來的分子診斷市場的相關分析，包含各類別、各地區市場預測、有主力產品的企業簡介等，概述如下。
總綱
第1章 導論
第2章 動向與促進因子
- 摘要
- 與傳統型實驗室的統合
- 次世代的超高感度分子診斷
- 課題與問題
第3章 市場發展
- 摘要
- 由組織抽出微RNA
- 囊胞性線維症的基因監測
- PET掃描
- Medicare對象之擴大
- Ionian Technologies與Roche的合作
- 白血病診斷試藥
- 新的肺癌檢査
- AMD診斷
- 主要生物標記基因
- 醫護站裝置
- 基因種類檢査之導入
- 革新的結腸癌診斷
- 革新的胰臓癌診斷
- 用於腦瘤的伴隨診斷
- Acrometrix的併購
- 即時PCR
- ApiX檢驗試劑
- 生物標記分析
- 基因皮膚科學
- 基因定序
第4章 市場
第5章 企業簡介
圖表
Abstract
Molecular diagnostics, essentially the analysis of DNA and RNA at the
molecular level, is a fast-growing business, made possible by the growing
understanding of the human genome, which has spurred growth in the diagnostic
business. Given the established importance of DNA in molecular biology and its
central role in determining the fundamental operation of cellular processes,
molecular diagnostics is making it possible to detect infectious disease and
cancer more accurately at an earlier stage than before. The technology also is
optimizing testing for sexually transmitted diseases and genetic testing.
Molecular diagnostics is also addressing the need for tests that monitor the
therapeutic efficacy of pharmaceuticals. In this way, it has evolved into an
important business opportunity for in-vitro diagnostics makers. Molecular
diagnostics is expanding beyond just the identification of infections. It is
becoming an integral part of disease management and therapy, finding such
applications as patient stratification, drug regimen selection, toxicity
avoidance, therapeutic monitoring, and detection of predisposition to disease.
Hospitals and diagnostic laboratories using molecular diagnostic techniques
need products that guarantee the highest levels of reliability and the
greatest speed. Reliability is essential, because an inaccurate or missed
diagnosis can be a matter of life and death. Another issue driving the need
for new molecular diagnostics involves the ability of microorganisms to evade
and even inactivate potent antibiotics, causing health care givers to be faced
with substantial infectious disease challenges. The variety of technologies
used in molecular diagnostics has transformed clinical laboratory medicine.
This report analyzes the current and potential world markets for molecular
diagnostics, including advances in the field. It also breaks down market
forecasts by type of test and by geography. This report indicates which
companies have key products in the market place and it also analyzes key
drivers of this market.
Table of Contents
Executive summary
- Introduction
- Trends and drivers
- Market developments
- Markets
Chapter1 Introduction
- Summary
- Perspective
- Perspective
- An emerging science
- Understanding the human genome
- Molecular level analysis
- Personalized care
- Individualized response
- Early-stage diagnosis
- Infectious disease
- Viruses
- Oncology
- Diagnostics business opportunity
- A growing role in diagnostics
- Companion diagnostics and therapies
- Diagnostics allowing early detection and treatment
- Increased efficiency
- Optimizing drug therapy
- Significant regulatory concerns
- Strengthening oversight
- Improving patient outcomes
- Optimizing instrumentation and chemistries
- Advances in sample preparation needed
- Automation
Chapter2 Trends and drivers
- Summary
- Integral to traditional labs
- Improved assay/test efficiencies
- Targeting antibiotic resistance
- Next generation ultrasensitive molecular diagnostics
- Platform variety
- PCR
- Microfluidics
- Biochips/microarrays
- Others
- Challenges and issues
- Re-emergence of infectious diseases and other threats
- Establishing accepted regulatory processes
- Reimbursement
- Medicare coverage
Chapter3 Market developments
- Summary
- Extracting microRNAs from tissue
- Cystic fibrosis genetic screening
- PET scanning
- Expanded medicare coverage
- Ionian Technologies-Roche collaboration
- Leukemia diagnostic kit cleared
- New lung cancer test
- AMD diagnostic
- Key biomarker gene
- Point of care instrumentation
- Genotyping test launch
- Innovative colon cancer diagnostic
- Innovative pancreatic cancer diagnostic
- Brain cancer companion diagnostic
- Rapid thermocycling
- Acquisition of AcroMetrix
- Real-time PCR
- APiX detection kit
- Biomarker analysis
- Genetic dermatology
- Genome sequencing agreement
Chapter4 Markets
- Summary
- Overview
- World market forecasts
- Geographical segmentation
- Type of testing
- Blood screening
- HPV testing
- Hospital acquired infections
- HIV/HCV testing
- Genetic testing
- Oncology
- STD testing
Chapter5 Corporate profiles
- Abbott Molecular
- AcroMetrix
- Adnavance Technologies Inc.
- Affymetrix
- Asuragen Inc.
- AutoGenomics Inc.
- Beckman Coulter Inc.
- Becton Dickinson
- Biocartis SA
- BioHelix
- bioMerieux SA
- Bio-Rad Laboratories Inc.
- Celera
- Cepheid
- CombiMatrix Corp.
- Cytocell Ltd.
- DiagnoCure Inc.
- Diasorin SpA
- Dx Assays
- EliTech Group
- Enzo Biochem
- EraGen Biosciences
- Fujirebio Diagnostics Inc.
- Gen-Probe Inc.
- Gene Express Inc.
- GE Healthcare
- Genomic Health Inc.
- IBT Laboratories
- Illumina Inc.
- IntelligentMDx
- InVivoScribe Technologies Inc.
- IRIS International Inc.
- Kreatech Diagnostics
- Luminex Molecular Diagnostics Inc.
- Myriad Genetics Inc.
- Nanosphere Inc.
- Norgen Biotek
- Novartis International AG
- OncoVista Inc.
- Pall Gene Systems
- Pathwork Diagnostics
- PrimeraDx
- Orion Genomics
- Osmetech Molecular Diagnostics
- Qiagen NV
- RedPath Integrated Pathology Inc.
- Roche Diagnostics
- Rosetta Genomics Ltd.
- Seegene
- Siemens Healthcare
- Singulex
- Thorne Diagnostics Inc.
- TrovaGene Inc.
- Veridex LLC
- Vita Genomics Inc.
Chapter6 Appendix
- Methodology
- Glossary
- Endnotes
- Index
List of Figures
- Figure 1.1: Molecular diagnostics: predicting response, early treatment of
disease
- Figure 2.2: Molecular Diagnostics
- Figure 2.3: Integrating molecular diagnostics with therapeutics
- Figure 2.4: Changing treatment protocols in clinical practice
- Figure 3.5: Clinical potential of molecular diagnostics
- Figure 3.6: Molecular diagnostics: challenges for developers
- Figure 5.7: World Market for molecular diagnostics by geography, 2010
- Figure 5.8: World Market for molecular diagnostics by application, 2010
- Figure 5.9: Molecular diagnostics diagnosing cancer
List of Tables
- Table 5.1: Key players in molecular diagnostics
- Table 5.2: World market for molecular diagnostics, 2009-2015, ($m)
- Table 5.3: World Market for molecular diagnostics by geography, 2010, ($m)
- Table 5.4: World Market for molecular diagnostics by application, 2010,
($m)
- Table 5.5: Molecular diagnostics blood screening market, breakup by
competition, ($m)
- Table 5.6: Molecular diagnostics HPV testing market, breakup by
competition, ($m)
- Table 5.7: Molecular diagnostics hospital acquired infections testing
market, breakup by competition, ($m)
- Table 5.8: Molecular diagnostics HIV/HCV testing market, breakup by
competition, ($m)
- Table 5.9: Molecular diagnostics genetic testing market, breakup by
competition, ($m)
- Table 5.10: Molecular diagnostics oncology testing market, breakup by
competition, ($m)
- Table 5.11: Molecular diagnostics STD testing market, breakup by company,
($m)
|
